Construction crews will fix NYC’s buckled former Pfizer building by lifting sagging floors 1/64th of an inch at a time up to ...

Substatial progress has been made on the elimination of trachoma but challenges in terms of funding and diagnostics remain. Timothy Jesudason reports.

Delve into Labiotech's October oncology roundup and find out about the news that caught our attention this last month.

Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L'Oreal are testing treatments for consumers ...

For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of ...

In the latest trading session, Pfizer (PFE) closed at $30.11, marking a +2.28% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.28%. Meanwhile, the ...

T-Cell Engager Therapeutics Market to grow from USD 7.2 Bn in 2026 to USD 39.4 Bn by 2036 at a 18.5% CAGR. Get segment, region & competitor insights.

This article is a personal record by the author (me) and does not recommend buying or selling any specific stocks. Figures ...

Pfizer Inc. (ISIN US7170811035) was trading at EUR 26.39 at Lang & Schwarz on October 20, 2026, 1.03 percent above the Xetra ...

A rotation out of artificial-intelligence-driven tech names into higher-yielding, defensive healthcare stocks is gathering ...

This is a small sample size, of course, but it may be the start of a new trend emerging, with investors pivoting to safer stocks that offer high yields. The healthcare sector is full of them, with ...

Pfizer's 5.8% yield looks tempting until you check what the dividend is actually costing the company relative to its cash ...